- Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet
- Joseph Truitt, Chief Operating Officer, promoted to President of Achillion
- Achillion seeking to generate additional datasets with ACH-4471 in both C3G and PNH programs in 2018
- Conference call scheduled for today at 8:30 a.m. EST
NEW HAVEN, Conn., Feb. 22, 2018 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical stage biopharmaceutical company focused on developing inhibitors of the complement alternative pathway, today announced an operational restructuring plan that aims to focus the organization on advancing Achillions existing clinical …
Read the full article at: https://globenewswire.com/news-release/2018/02/22/1379702/0/en/Achillion-Announces-Restructuring-to-Advance-Corporate-Strategy-Announces-2017-Fourth-Quarter-and-Full-Year-Financial-Results.html